Saptagir To Manufacture Corona Anti-viral Drug 'Remdesivir'
Category: Coronavirus
saptagir-to-manufacture-corona-antiviral-drug-remdesivir_g2d

Hyderabad-based API (Active Pharmaceutical Ingredient) and intermediate innovator Saptagir Laboratories — part of the 900 crore Saptagir Group — have announced an exclusive agreement with Jubilant Generics, a Jubilant Life Sciences firm, to develop intermediates and APIs for Remdesivir intravenous medication. The drug will be manufactured at the GMP-certified sterile drug product manufacturing plant of Hyderabad WHO that was acquired at an investment of Rs 75 crores. Fresh investment in a pharmaceutical plant approved by WHO-GMP gives Saptagir a clear entry into an adjacent pharmaceutical vertical.

"The strategy is to achieve USFDA certification for the plant and establish strong partnerships with a goal of achieving 500 KL potential in the coming years," said Saptagir Laboratories, Promoter and Managing Director, Shilpa Reddy. The Saptagir Group has many product development achievements in molecules previously produced only in China. "This partnership meets the needs of our global customers who support India as a strong second source of goods beyond China. With the new investment of Rs 75 crore at the Hyderabad pharmaceutical plant, we will further expand our presence in the health and wellness market," said Mahesh Reddy, the company's Promoter and Chairman.

Remdesivir is an antiviral experimental drug developed by Gilead Sciences, Inc., as a treatment course for Covid-19. Gilead signed a non-exclusive licence deal for sale to 127 countries with Jubilant Life Sciences. After this, Jubilant Life Sciences has entered into an exclusive agreement with Saptagir Laboratories to produce Remdesivir through its subsidiary Jubilant Generics. Remdesivir is currently the only drug that has received a Food and Drug Administration (FDA) Emergency Use Authorisation, and has been approved for emergency use in countries such as Singapore, the United States and India, Australia, for the treatment of the novel coronavirus.

According to Gilead Life Sciences — the patent holder — the demand for Remdesivir is projected at USD 2.3 trillion for this year and the next year, based on their understanding of the situation. Given that the world continues to experience an increase in the number of new cases of coronavirus, the availability of life-saving anti-covidic drugs is desperately required. Saptagir Camphor, Saptagir Laboratories' Flagship Group Company, is India's largest and second-largest manufacturer of Camphor and many other aromatic ingredients that support the world's largest manufacturer of flavour and fragrance.

0 167
Posted Comments
FEEDBACK
@ galli2delhi.com All Rights Reserved
@ galli2delhi.com All Rights Reserved